Foghorn Stock Based Compensation from 2010 to 2024

FHTX Stock

USD 7.72 0.14 1.78%

Foghorn Therapeutics Stock Based Compensation yearly trend continues to be fairly stable with very little volatility. Stock Based Compensation will likely drop to about 8.1 M in 2024. Stock Based Compensation is compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders. View All Fundamentals

Stock Based Compensation

First Reported

2018-03-31

Previous Quarter

3.2 M

Current Value

3 M

Quarterly Volatility

1.5 M

Covid

Check Foghorn Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Foghorn Therapeutics' main balance sheet or income statement drivers, such as Net Interest Income of 11.1 M, Interest Income of 11.1 M or Depreciation And Amortization of 3.9 M, as well as many indicators such as Price To Sales Ratio of 7.53, Dividend Yield of 0.0 or Days Sales Outstanding of 66.4 K. Foghorn financial statements analysis is a perfect complement when working with Foghorn Therapeutics Valuation or Volatility modules.

Check out the analysis of Foghorn Therapeutics Correlation against competitors.

For more information on how to buy Foghorn Stock please use our How to Invest in Foghorn Therapeutics guide.

Latest Foghorn Therapeutics' Stock Based Compensation Growth Pattern

Below is the plot of the Stock Based Compensation of Foghorn Therapeutics over the last few years. It is compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders. Foghorn Therapeutics' Stock Based Compensation historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Foghorn Therapeutics' overall financial position and show how it may be relating to other accounts over time.

Stock Based Compensation

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Stock Based Compensation

Timeline

Foghorn Stock Based Compensation Regression Statistics

	Arithmetic Mean	3,884,626
	Geometric Mean	1,759,151
	Coefficient Of Variation	136.54
	Mean Deviation	4,198,384
	Median	732,000
	Standard Deviation	5,303,937
	Sample Variance	28.1T
	Range	15.5M
	R-Value	0.76
	Mean Square Error	12.9T
	R-Squared	0.57
	Significance	0
	Slope	898,863
	Total Sum of Squares	393.8T

Foghorn Stock Based Compensation History

	2024	8.1 M
	2023	16.2 M
	2022	14.3 M
	2021	8.4 M
	2020	3 M
	2019	1.7 M

Other Fundumenentals of Foghorn Therapeutics

Stock Based Compensation To Revenue

Foghorn Therapeutics Stock Based Compensation component correlations

	Total Assets	Total Stockholder Equity	Net Tangible Assets	Net Debt	Retained Earnings	Accounts Payable	Long Term Debt	Total Liab	Net Invested Capital	Total Current Assets	Net Working Capital	Common Stock	Property Plant Equipment	Current Deferred Revenue	Short Long Term Debt	Short Term Debt	Net Receivables	Short Term Investments	Capital Surpluse
Total Assets		0.55	0.73	-0.48	-0.8	0.78	0.89	0.93	0.49	1.0	0.99	0.92	0.91	0.54	-0.33	0.87	0.65	0.43	0.73
Total Stockholder Equity	0.55		0.91	-0.09	-0.06	0.1	0.47	0.23	1.0	0.52	0.57	0.48	0.59	0.1	0.31	0.18	0.53	-0.14	-0.08
Net Tangible Assets	0.73	0.91		-0.06	-0.41	0.41	0.71	0.46	0.89	0.7	0.73	0.75	0.83	0.11	-0.09	0.51	0.51	0.0	0.28
Net Debt	-0.48	-0.09	-0.06		0.41	-0.45	-0.36	-0.55	-0.05	-0.48	-0.48	-0.38	-0.33	-0.99	-0.06	-0.33	0.02	-0.88	-0.37
Retained Earnings	-0.8	-0.06	-0.41	0.41		-0.95	-0.84	-0.88	-0.01	-0.79	-0.75	-0.89	-0.83	-0.51	0.74	-0.95	-0.21	-0.64	-0.96
Accounts Payable	0.78	0.1	0.41	-0.45	-0.95		0.92	0.86	0.07	0.76	0.71	0.9	0.85	0.56	-0.55	0.91	0.16	0.66	0.91
Long Term Debt	0.89	0.47	0.71	-0.36	-0.84	0.92		0.85	0.44	0.86	0.84	0.98	0.97	0.47	-0.34	0.89	0.39	0.46	0.78
Total Liab	0.93	0.23	0.46	-0.55	-0.88	0.86	0.85		0.16	0.94	0.92	0.86	0.81	0.62	-0.41	0.94	0.56	0.56	0.88
Net Invested Capital	0.49	1.0	0.89	-0.05	-0.01	0.07	0.44	0.16		0.47	0.51	0.44	0.55	0.06	0.34	0.12	0.48	-0.17	-0.13
Total Current Assets	1.0	0.52	0.7	-0.48	-0.79	0.76	0.86	0.94	0.47		1.0	0.9	0.89	0.54	-0.32	0.87	0.68	0.42	0.73
Net Working Capital	0.99	0.57	0.73	-0.48	-0.75	0.71	0.84	0.92	0.51	1.0		0.87	0.87	0.53	-0.28	0.83	0.71	0.39	0.68
Common Stock	0.92	0.48	0.75	-0.38	-0.89	0.9	0.98	0.86	0.44	0.9	0.87		0.99	0.47	-0.45	0.91	0.38	0.49	0.82
Property Plant Equipment	0.91	0.59	0.83	-0.33	-0.83	0.85	0.97	0.81	0.55	0.89	0.87	0.99		0.43	-0.39	0.86	0.42	0.42	0.73
Current Deferred Revenue	0.54	0.1	0.11	-0.99	-0.51	0.56	0.47	0.62	0.06	0.54	0.53	0.47	0.43		-0.01	0.41	0.0	0.91	0.45
Short Long Term Debt	-0.33	0.31	-0.09	-0.06	0.74	-0.55	-0.34	-0.41	0.34	-0.32	-0.28	-0.45	-0.39	-0.01		-0.59	0.09	-0.32	-0.68
Short Term Debt	0.87	0.18	0.51	-0.33	-0.95	0.91	0.89	0.94	0.12	0.87	0.83	0.91	0.86	0.41	-0.59		0.44	0.47	0.96
Net Receivables	0.65	0.53	0.51	0.02	-0.21	0.16	0.39	0.56	0.48	0.68	0.71	0.38	0.42	0.0	0.09	0.44		-0.28	0.22
Short Term Investments	0.43	-0.14	0.0	-0.88	-0.64	0.66	0.46	0.56	-0.17	0.42	0.39	0.49	0.42	0.91	-0.32	0.47	-0.28		0.58
Capital Surpluse	0.73	-0.08	0.28	-0.37	-0.96	0.91	0.78	0.88	-0.13	0.73	0.68	0.82	0.73	0.45	-0.68	0.96	0.22	0.58

Click cells to compare fundamentals

About Foghorn Therapeutics Financial Statements

Foghorn Therapeutics investors use historical fundamental indicators, such as Foghorn Therapeutics' Stock Based Compensation, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Foghorn Therapeutics. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Stock Based Compensation	16.2 M	8.1 M
Stock Based Compensation To Revenue	0.47	0.45

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

Additional Tools for Foghorn Stock Analysis

When running Foghorn Therapeutics' price analysis, check to measure Foghorn Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Foghorn Therapeutics is operating at the current time. Most of Foghorn Therapeutics' value examination focuses on studying past and present price action to predict the probability of Foghorn Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Foghorn Therapeutics' price. Additionally, you may evaluate how the addition of Foghorn Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Foghorn Stock Based Compensation from 2010 to 2024

Latest Foghorn Therapeutics' Stock Based Compensation Growth Pattern

Foghorn Stock Based Compensation Regression Statistics

Foghorn Stock Based Compensation History

Other Fundumenentals of Foghorn Therapeutics

Foghorn Therapeutics Stock Based Compensation component correlations

About Foghorn Therapeutics Financial Statements

Also Currently Popular

Additional Tools for Foghorn Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY